Technical Analysis for SESN - Sesen Bio, Inc.

Grade Last Price % Change Price Change
D 2.375 2.37% 0.06
SESN closed down 7.94 percent on Monday, April 12, 2021, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical SESN trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 5.60%
Lower Bollinger Band Touch Weakness 5.60%
Oversold Stochastic Weakness 5.60%
Oversold Stochastic Weakness -2.78%
50 DMA Resistance Bearish -5.77%
MACD Bearish Centerline Cross Bearish -5.77%
Oversold Stochastic Weakness -5.77%
Fell Below 50 DMA Bearish -5.22%
Stochastic Reached Oversold Weakness -5.22%
Oversold Stochastic Weakness -5.22%
Older End-of-Day Signals for SESN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 38 minutes ago
Up 5% 38 minutes ago
Up 3% 38 minutes ago
Up 2% about 2 hours ago
Up 1% about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sesen Bio, Inc. Description

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Oncology Monoclonal Antibodies Carcinoma Bladder Cancer Fusion Protein Checkpoint Inhibitor Causes Of Death Squamous Cell Carcinoma Therapies For Patients With Cancer

Is SESN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.57
52 Week Low 0.51
Average Volume 7,198,367
200-Day Moving Average 1.55
50-Day Moving Average 2.67
20-Day Moving Average 2.77
10-Day Moving Average 2.59
Average True Range 0.23
ADX 13.9
+DI 18.89
-DI 27.95
Chandelier Exit (Long, 3 ATRs ) 2.87
Chandelier Exit (Short, 3 ATRs ) 2.95
Upper Bollinger Band 3.23
Lower Bollinger Band 2.31
Percent B (%b) 0.01
BandWidth 33.44
MACD Line -0.05
MACD Signal Line 0.01
MACD Histogram -0.0567
Fundamentals Value
Market Cap 300.07 Million
Num Shares 129 Million
EPS -1.05
Price-to-Earnings (P/E) Ratio -2.22
Price-to-Sales 13.15
Price-to-Book 5.98
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.69
Resistance 3 (R3) 2.71 2.60 2.63
Resistance 2 (R2) 2.60 2.51 2.59 2.61
Resistance 1 (R1) 2.46 2.45 2.41 2.44 2.59
Pivot Point 2.36 2.36 2.33 2.35 2.36
Support 1 (S1) 2.22 2.26 2.16 2.20 2.05
Support 2 (S2) 2.11 2.20 2.10 2.03
Support 3 (S3) 1.97 2.11 2.01
Support 4 (S4) 1.95